Neoadjuvant Niraparib Plus Dostarlimab Data Support Development of Non-Chemo Approaches in BRCA+, ER+ Breast Cancer

FDA Fast Tracks Emiltatug Ledadotin in Advanced/Metastatic Breast Cancer

The FDA has granted fast track designation to emiltatug ledadotin for advanced or metastatic breast cancer treatment, as supported by new phase 1 data.

Neoadjuvant Niraparib Plus Dostarlimab Data Support Development of Non-Chemo Approaches in BRCA+, ER+ Breast Cancer

Erica L. Mayer, MD, MPH, responses with preoperative niraparib plus dostarlimab in patients with BRCA-mutant, ER-positive, HER2-negative breast cancer.

ICR welcomes NICE recommendation of olaparib for advanced breast cancer

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for locally advanced or metastatic breast cancer. The judgement makes this pioneering treatment available on the NHS for people with HER2-negative breast cancer, caused by faulty BRCA1 or BRCA2 genes, which has advanced or spread following chemotherapy. The treatment offers the chance of longer, healthier live…